Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GDC-0917 · CUDC-427

Small molecule · Antagonist of XIAP, cIAP1 (BIRC2) and cIAP2 (BIRC3) · developed by Curis

Phase 1 Most advanced trial (none active)
CRIS Developer
1 Registered trials

What is GDC-0917?

GDC-0917 is an orally available Smac mimetic that binds to inhibitor of apoptosis proteins (IAPs), including XIAP and cellular IAPs 1 and 2, blocking their anti-apoptotic function. It promotes apoptosis in cancer cells by preventing IAPs from inhibiting caspases. The drug is studied in lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CUDC-427
Drug type
Small molecule
Targets
XIAP, cIAP1 (BIRC2), cIAP2 (BIRC3)
Mechanism
Antagonist of XIAP, cIAP1 (BIRC2) and cIAP2 (BIRC3)
Pathways
apoptosis
Therapy area
Oncology
Developer
Curis, Inc. (CRIS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
KWH46ZDG32

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01908413 Phase 1 Lymphoma Terminated CRIS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lymphoma

Other drugs acting on XIAP / BIRC2 / BIRC3

Birinapant Phase 1/2 Dasminapant Phase 1/2

More from Curis

Cenopodlin Phase 1 CUDC-101 Phase 1 Emavusertib Phase 1/2 Fimepinostat Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CRIS page.

Follow CRIS, the company behind GDC-0917

See CRIS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRIS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.